Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Exclusion Criteria

• •Participant has a history of another malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hyperplasia, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years before the date of enrollment). History of hematopoietic allogenic transplantation.
• •Participants with known brain metastases, except those meeting both of the following criteria:
• •1. All brain metastases have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment.
• •2. No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable).
• •Participants with diarrhea (liquid stool) or ileus Grade more than (\>) 1 within 1 week of Cycle1Day1.
• •Participants with active chronic inflammatory bowel disease and/or bowel obstruction.
• •Participants with history of serious gastrointestinal bleeding within 3 months of Cycle1Day1.